MAP2K7 and melanoma: Targeted therapy that specifically inhibits BRAF and MEK pathways also inhibit glycolysis and is nowadays the mainstay of melanoma therapy; since an increase in oxidative phosphorylation has been reported to contribute to drug resistance, the inhibition of mitochondrial respiration has emerged as viable therapeutic strategy to overcome the resistance to pharmacological inhibitors [30,31].